PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33118159-6 2021 Pertussis toxin, Gi/o inhibitor, but not YM-254890, Gq inhibitor, and NF499, Gs inhibitor, inhibited LPA-induced TSP-1 production, indicating LPA increases TSP-1 production through Gi/o-coupled LPA1 and LPA3 receptors. lysophosphatidic acid 101-104 lysophosphatidic acid receptor 3 Rattus norvegicus 203-207 33118159-6 2021 Pertussis toxin, Gi/o inhibitor, but not YM-254890, Gq inhibitor, and NF499, Gs inhibitor, inhibited LPA-induced TSP-1 production, indicating LPA increases TSP-1 production through Gi/o-coupled LPA1 and LPA3 receptors. lysophosphatidic acid 142-145 lysophosphatidic acid receptor 3 Rattus norvegicus 203-207 30283359-0 2018 Lysophosphatidic Acid Is Associated With Cardiac Dysfunction and Hypertrophy by Suppressing Autophagy via the LPA3/AKT/mTOR Pathway. lysophosphatidic acid 0-21 lysophosphatidic acid receptor 3 Rattus norvegicus 110-114 30283359-11 2018 In addition, we found that knockdown of LPA3 alleviated LPA-mediated autophagy suppression in H9C2 cardiomyoblasts, suggesting that LPA suppresses autophagy through activation of the LPA3 and AKT/mTOR pathways. lysophosphatidic acid 40-43 lysophosphatidic acid receptor 3 Rattus norvegicus 183-187 30283359-11 2018 In addition, we found that knockdown of LPA3 alleviated LPA-mediated autophagy suppression in H9C2 cardiomyoblasts, suggesting that LPA suppresses autophagy through activation of the LPA3 and AKT/mTOR pathways. lysophosphatidic acid 56-59 lysophosphatidic acid receptor 3 Rattus norvegicus 40-44 30283359-11 2018 In addition, we found that knockdown of LPA3 alleviated LPA-mediated autophagy suppression in H9C2 cardiomyoblasts, suggesting that LPA suppresses autophagy through activation of the LPA3 and AKT/mTOR pathways. lysophosphatidic acid 56-59 lysophosphatidic acid receptor 3 Rattus norvegicus 183-187 30283359-12 2018 Conclusion: These findings suggest that LPA plays an important role in mediating cardiac dysfunction and hypertrophy after a MI, and that LPA suppresses autophagy through activation of the LPA3 and AKT/mTOR pathways to induce cardiomyocyte hypertrophy. lysophosphatidic acid 138-141 lysophosphatidic acid receptor 3 Rattus norvegicus 189-193 28376314-2 2017 LPA contributes to embryo implantation via the lysophospholipid LPA3 receptor. lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 64-68 28376314-11 2017 The results show that the disruption of endogenous LPA signalling by blocking the LPA3 receptor modified the development of uterine vessels with consequences in the formation of the decidua and placenta and in the growth of embryos. lysophosphatidic acid 51-54 lysophosphatidic acid receptor 3 Rattus norvegicus 82-86 25400583-6 2014 Inhibition of LPA signaling via blockade of the LPA G-protein coupled receptors LPAR1 and LPAR3 with 10 muM Ki16425 reduced the LPA-enhanced adhesion of VSCM to FN by 40% (P < 0.05). lysophosphatidic acid 14-17 lysophosphatidic acid receptor 3 Rattus norvegicus 90-95 28922661-0 2017 Lysophosphatidic Acid Inhibits Insulin Signaling in Primary Rat Hepatocytes via the LPA3 Receptor Subtype and is Increased in Obesity. lysophosphatidic acid 0-21 lysophosphatidic acid receptor 3 Rattus norvegicus 84-88 28922661-11 2017 CONCLUSION: LPA is able to interrupt insulin signaling in primary rat hepatocytes via the LPA3 receptor subtype. lysophosphatidic acid 12-15 lysophosphatidic acid receptor 3 Rattus norvegicus 90-94 25400583-12 2014 These results indicate that, in VSMC, LPA-induced integrin activation involves the G-protein coupled receptors LPAR1 and LPAR3, and the production of ROS, and that LPA may play an important role in the control of myogenic behavior in resistance vessels through ROS modulation of integrin activity. lysophosphatidic acid 38-41 lysophosphatidic acid receptor 3 Rattus norvegicus 121-126 23029388-12 2012 Also, LPA augmented via LPA3 decidualization and vascularization markers. lysophosphatidic acid 6-9 lysophosphatidic acid receptor 3 Rattus norvegicus 24-28 23790320-5 2013 METHODS: We adopted a pharmacological approach in vitro incubating the uterus from rats on day 5 of gestation (day of implantation) with LPA, DGPP (a highly selective antagonist of LPA3, an LPA receptor) and cyclooxygenase and NOS selective and non-selective inhibitors. lysophosphatidic acid 137-140 lysophosphatidic acid receptor 3 Rattus norvegicus 181-222 23790320-7 2013 RESULTS: We observed that LPA augmented the activity of the inducible NOS isoform through LPA1/LPA3. lysophosphatidic acid 26-29 lysophosphatidic acid receptor 3 Rattus norvegicus 95-99 23711961-5 2013 Experiments were done with cultured neonatal rat cardiomyocytes (NRCMs) exposed to LPA and we showed that knockdown of LPA1 by small interfering RNA (siRNA) enhanced LPA-induced cardiomyocyte hypertrophy, whereas LPA3 silencing repressed hypertrophy. lysophosphatidic acid 119-122 lysophosphatidic acid receptor 3 Rattus norvegicus 213-217 23711961-9 2013 And PI3K inhibitor, LY294002, effectively prevented LPA-induced miR-23a expression in cardiomyocytes, suggesting that LPA might induce miR-23a elevation by activating LPA3 and PI3K/AKT pathway. lysophosphatidic acid 52-55 lysophosphatidic acid receptor 3 Rattus norvegicus 167-171 23711961-9 2013 And PI3K inhibitor, LY294002, effectively prevented LPA-induced miR-23a expression in cardiomyocytes, suggesting that LPA might induce miR-23a elevation by activating LPA3 and PI3K/AKT pathway. lysophosphatidic acid 118-121 lysophosphatidic acid receptor 3 Rattus norvegicus 167-171 12724320-2 2003 LPA has been widely considered to elicit its biological functions through three types of G protein-coupled receptors, Edg-2 (endothelial cell differentiation gene-2)/LPA1/vzg-1 (ventricular zone gene-1), Edg-4/LPA2, and Edg-7/LPA3. lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 220-225 19757175-6 2010 LPA-induced cell phenotypic modulation was significantly inhibited by specific LPA1/LPA3-receptor antagonist dioctyl-glycerol pyrophosphate (DGPP8:0) at concentration, but this inhibitive effect was lost when the antagonist was coadministered with a highly selective LPA3 agonist,1-oleoyl-2-Omethyl-rac-glycero-phosphothionate (OMPT). lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 84-88 19757175-6 2010 LPA-induced cell phenotypic modulation was significantly inhibited by specific LPA1/LPA3-receptor antagonist dioctyl-glycerol pyrophosphate (DGPP8:0) at concentration, but this inhibitive effect was lost when the antagonist was coadministered with a highly selective LPA3 agonist,1-oleoyl-2-Omethyl-rac-glycero-phosphothionate (OMPT). lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 267-271 19757175-8 2010 These data suggest that LPA-induced phenotypic modulation is mediated through the PTX-insensitive G-protein(s), possibly Gq-coupled LPA3 receptor. lysophosphatidic acid 24-27 lysophosphatidic acid receptor 3 Rattus norvegicus 132-136 19742132-5 2009 LPA-induced cell migration was significantly inhibited by specific LPA1/LPA3-receptor antagonist Dioctylglycerol pyrophosphate (8:0) (DGPP8.0) at higher concentration. lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 72-76 17891781-4 2008 In NRCMs, LPA-induced hypertrophic growth was completely abrogated by DGPP, an LPA1/LPA3 antagonist. lysophosphatidic acid 10-13 lysophosphatidic acid receptor 3 Rattus norvegicus 84-88 12724320-2 2003 LPA has been widely considered to elicit its biological functions through three types of G protein-coupled receptors, Edg-2 (endothelial cell differentiation gene-2)/LPA1/vzg-1 (ventricular zone gene-1), Edg-4/LPA2, and Edg-7/LPA3. lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 226-230 12123830-1 2002 Lysophosphatidic acid (LPA) exerts multiple biological functions through G protein-coupled receptors (EDG2/LPA(1), EDG4/LPA(2), and EDG7/LPA(3)) and is present in serum where it is associated with albumin. lysophosphatidic acid 0-21 lysophosphatidic acid receptor 3 Rattus norvegicus 132-143 12123830-1 2002 Lysophosphatidic acid (LPA) exerts multiple biological functions through G protein-coupled receptors (EDG2/LPA(1), EDG4/LPA(2), and EDG7/LPA(3)) and is present in serum where it is associated with albumin. lysophosphatidic acid 23-26 lysophosphatidic acid receptor 3 Rattus norvegicus 132-143 12123830-8 2002 The present study shows that serum albumin can negatively regulate EDG7 but not EDG2 or EDG4, and suggests that protein factors are present in seminal plasma and deliver LPA efficiently to EDG7 but not to EDG2 or EDG4. lysophosphatidic acid 170-173 lysophosphatidic acid receptor 3 Rattus norvegicus 189-193 11723223-0 2001 Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. lysophosphatidic acid 49-52 lysophosphatidic acid receptor 3 Rattus norvegicus 100-104 10891327-0 2000 Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid. lysophosphatidic acid 77-98 lysophosphatidic acid receptor 3 Rattus norvegicus 21-25 10488122-4 1999 LPA (oleoyl) but not other lysophospholipids induced an increase in the [Ca(2+)](i) of EDG7-overexpressing Sf9 cells. lysophosphatidic acid 0-3 lysophosphatidic acid receptor 3 Rattus norvegicus 87-91 10488122-7 1999 In EDG7- or EDG4-expressing Sf9 cells, LPA stimulated forskolin-induced increase in intracellular cAMP levels, which was not observed in EDG2-expressing cells. lysophosphatidic acid 39-42 lysophosphatidic acid receptor 3 Rattus norvegicus 3-7